Drugs / TIL
last change Jun 2025 re-read 2 minutes ago

TIL

Cell therapy

Developed for
metastatic melanoma
Investigated by
TILT Biotherapeutics Ltd.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06961786 Jun 2025 → Nov 2026 expected metastatic melanoma TILT Biotherapeutics Ltd. Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TIL ClinicalTrials.gov intervention name — accepted as the source's own label NCT06961786
Modality Cell therapy “Adoptive T cell therapy with TILs” NCT06961786